Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review

Pulmonary Pharmacology and Therapeutics

Volumn 22, Issue 1, 2009, Pages 9-19

  Rodrigo, Gustavo J ^a,b   Moral, Vicente Plaza ^c   Marcos, Luis García ^d   Castro Rodriguez, José A ^e  

^a HOSPITAL CENTRAL DE LAS FUERZAS ARMADAS   (Uruguay)

^b Facultad de Medicina Claeh Prado y Salt Lake   (Uruguay)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Asthma; Bronchodilators; Formoterol; Inhaled corticosteroids; Long acting beta agonists; Safety; Salmeterol

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; PLACEBO; SALMETEROL;

ACUTE RESPIRATORY FAILURE; ADD ON THERAPY; ARTICLE; ASTHMA; CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE STUDY; DATA BASE; DEATH; DISEASE EXACERBATION; DRUG EFFECT; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EMBASE; HOSPITALIZATION; HUMAN; LIFE; MEDLINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTECTION; RISK; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CHILD; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 58749100633     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2008.10.008     Document Type: Article

References (117)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Available from: (Revised 2007). http://www:ginasthma.com [accessed 22.12.07]
2. National Heart, Lung, and Blood Institute. Expert panel report 3: guidelines for de diagnosis and management of asthma (2007), National Institutes of Health, Bethesda, MD. http://www.nhlbi.nih.gov [accessed 10.12.07]
3. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., Dorinsky P.M., and The Salmeterol Multicenter Asthma Research Trial. A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
4. Food and Drug Administration, and Pulmonary-Allergy Drugs Advisory Committee. Briefing information. Available from: (June 13, 2005). http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4148%20index%20with %20disclaimer-13.htm [accessed 06.10.07]
5. Salpeter S.R., Buckley N.S., Ormiston T.M., and Salpeter E.E. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144 (2006) 904-912
6. Walters E.H., Gibson P.G., Lasserson T.J., and Walters J.A.E. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev Issue 1 (2007) Art. No.: CD001385
7. Greenstone I.R., Ni Chroinin M., Masse V., Danish A., Magdalinos H., Zhang X., et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev Issue 4 (2005) Art. No.: CD005533
8. Ni Chroinin M., Greenstone I.R., Danish A., Magdolinos H., Masse V., Zhang X., et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev Issue 4 (2005) Art. No.: CD005535
9. Cates C.J., and Cates M.J. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev Issue 3 (2008) Art. No.: CD006363
10. Bateman E., Nelson H., Bousquet J., Kral K., Sutton L., Ortega H., et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med (June 3, 2008) [Epub ahead of print]
11. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 354 (1999) 1896-1900
12. Jadad A.R., Moore R.A., Carrol D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized controlled trials: is blinding necessary?. Control Clin Trials 17 (1996) 1-12
13. Higgins J.P.T., Thompson S.G., Deecks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
14. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959) 719-748
15. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
16. Altman D.G., and Bland J.M. Interaction revisited: the difference between two estimates. BMJ 326 (2003) 219
17. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
18. Bensch G., Lapidus R.J., Levine B.E., Lumry W., Yergen U., Kiselev P., et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 86 (2001) 19-27
19. Bensch G., Berger W.E., Blokhin B.M., Socolovsky A.L., Thomson M.H., Till M.D., et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 89 (2002) 180-190
20. Boyd G. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group. Eur Respir J 8 (1995) 1494-1498
21. Busse W., Levine B., Andriano K., Lavecchia C., and Yegen U. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study. Clin Ther 26 (2004) 1587-1598
22. Cloosterman S.G., Bijl-Hofland I.D., van Herwaarden C.L., Akkermans R.P., van Den Elshout F.J., Folgering H.T., et al. A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients. Chest 119 (2001) 1306-1315
23. D'Alonzo G.E., Nathan R.A., and Henchowicz M.D. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 271 (1994) 1412-1416
24. D'Urzo A.D., Chapman K.R., Cartier A., Hargreave F.E., Fitzgerald M., and Tesarowski D. Effectiveness and safety of salmeterol in nonspecialist practice settings. Chest 119 (2001) 714-719
25. Ekstrom T., Ringdal N., Sobradillo V., Runnerstrom E., and Soliman S. Low-dose formoterol Turbuhaler (Oxis) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.). Respir Med 92 (1998) 1040-1045
26. GlaxoSmithKline Clinical Trial Register. Salmeterol SLGA 2004 trial. Available from: http://ctr.gsk.co.uk/welcome.asp [accessed 6.10.07].
27. Kemp J.P., Cook D.A., Incaudo G.A., Corren J., Kalberg C., Emmett A., et al. Salmeterol improves quality of life in patients with Asthma requiring inhaled corticosteroids. J Allergy Clin Immunol 101 (1998) 188-195
28. Kemp J., Wolfe J., Grady J., LaForce C., Stahl E., Arledge T., et al. Salmeterol powder compared with albuterol aerosol as maintenance therapy for asthma in adolescent and adult asthma patients. Clin Ther 20 (1998) 270-282
29. LaForce C., Prenner B.M., Andriano K., Lavecchia C., and Yegen U. Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma. J Asthma 42 (2005) 101-106
30. Lazarus S.C., Boushey H.A., Fahy J.V., Chinchilli V.M., Lemanske Jr. R.F., Sorkness C.A., et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 285 (2001) 2583-2593
31. Levy R., Pinnas J., Milgrom H., Smith J., and Yegen U. Safety and efficacy in children with persistent asthma treated with formoterol 10 mcg bid delivered via Certihaler: a novel multidose dry-powder inhaler. Pediatr Asthma Allergy Immunol 18 (2005) 25-35
32. Lockey R.F., DuBuske L.M., Friedman B., Petrocella V., Cox F., and Rickard K. Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes. Chest 115 (1999) 666-673
33. Nathan R., Pinnas J., Schwartz H., Grossman J., Yancey S., Emmett A., et al. A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent- asthma. Ann Allergy 82 (1999) 521-529
34. Nightingale J.A., Rogers D.F., and Barnes P.J. Comparison of the effects of salmeterol and formoterol in patients with severe asthma. Chest 121 (2002) 1401-1406
35. Norhaya M.R., Yap T.M., and Zainudin B.M. Addition of inhaled salmeterol inhaled corticosteroids in patients with poorly controlled nocturnal asthma. Respirology 4 (1999) 77-81
36. ® inhaler versus albuterol MDI and placebo in mild-to-moderate Asthma: a randomized, double-blind double-dummy trial. J Asthma 40 (2003) 505-514
37. Rosenthal R.R., Busse W.W., Kemp J.P., Baker J.W., Kalberg C., Emmett A., et al. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness. Chest 116 (1999) 595-602
38. Simons F.E. A comparison of beclomethasone, salmeterol, and placebo in children with Asthma. Canadian beclomethasone dipropionate-salmeterol xinafoate study group. N Engl J Med 337 (1997) 1659-1665
39. Steffensen I., Faurschou P., Riska H., Rostrup J., and Wegener T. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Allergy 50 (1995) 657-663
40. Taylor D.R., Town G.I., Herbison G.P., Boothman-Burrell D., Flannery E.M., Hancox B., et al. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax 53 (1998) 744-752
41. van der Molen T., Postma D.S., Turner M.O., Jong B.M., Malo J.L., Chapman K., et al. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators. Thorax 52 (1997) 535-539
42. von Berg A., de Blic J., la Rosa M., Kaad P.H., and Moorat A. A comparison of regular salmeterol vs 'as required' salbutamol therapy in asthmatic children. Respir Med 92 (1998) 292-299
43. von Berg A., Papageorgiou Saxoni F., Wille S., Carrillo T., Kattamis C., and Helms P.J. Efficacy and tolerability of formoterol Turbuhaler in children. Int J Clin Pract 57 (2003) 852-856
44. Weinstein S., Pearlman D., Bronsky E., Byrne A., Arledge T., Liddle R., et al. Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma. Ann Allergy Asthma Immunol 81 (1998) 51-58
45. Wilding P., Clark M., Thompson Coon J., Lewis S., Rushton L., Bennett J., et al. Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 314 (1997) 1441-1446
46. Wolfe J., LaForce C., Friedman B., Sokol W., Till D., Della Cioppa G., et al. Formoterol, 24 μg bid, and serious asthma exacerbations. Similar rates compared with formoterol, 12 μg bid, with and without extra doses taken on demand, and placebo. Chest 129 (2006) 27-38
47. U.S. Food and Drug Administration. Center for drug evaluation and review. Foradil (Formoterol Fumarate inhalation) aerolizer. Part 4 (2001). www.fda.gov/cder/foi/nda/2001/20831_Foradil_medr_P4.pdf [accessed 6.10.07]
48. U.S. Food and Drug Administration. Center for drug evaluation and review. Foradil (Formoterol Fumarate inhalation) aerolizer. Part 5 (2001). www.fda.gov/cder/foi/nda/2001/20831_Foradil_medr_P5.pdf [accessed 6.10.07]
49. U.S. Food and Drug Administration Center for Drug Evaluation and Review. Serevent (Salmeterol Xinafoate inhalation) diskus. Part 2 (2001). www.fda.gov/cder/foi/nda/98/20692S1,2_Serevent_medr_P2.pdf [accessed 6.10.07]
50. U.S. Food and Drug Administration. Serevent pivotal safety and efficacy: SLD-390 (2001). www.fda.gov/cder/foi/nda/98/20692S1,2_Serevent_medr_P1.pdf [accessed 6.10.07]
51. Zimmerman B., D'Urzo A., and Berube D. Efficacy and safety of formoterol Turbuhaler when added to inhaled corticosteroid treatment in children with asthma. Pediatr Pulmonol 37 (2004) 122-127
52. AstraZeneca Clinical Trial Register. SD-039-0681 trial. Available from: www.astrazenecaclinicaltrials.com/Article/S528021.aspx [accessed 2.11.07].
53. AstraZeneca Clinical Trial Register. SD-039-0682 trial. Available from: www.astrazenecaclinicaltrials.com/Article/S528020.aspx [accessed 2.11.07].
54. AstraZeneca Clinical Trial Register. SD-039-0714 trial. Available from: www.astrazenecaclinicaltrials.com/Article/S12766.aspx [accessed 2.11.07].
55. AstraZeneca Clinical Trial Register. SD-039-0719 trial. Available from: www.astrazenecaclinicaltrials.com/Article/528062.aspx [accessed 2.11.07].
56. AstraZeneca Clinical Trial Register. SD-039-0725 trial. Available from: www.astrazenecaclinicaltrials.com/Article/528061.aspx [accessed 2.11.07].
57. Aubier M., Pieters W.R., Schlosser N.J.J., and Steinmetz K.-O. Salmeterol/fluticasone propionate (50/500 mcg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 93 (1999) 876-884
58. Baraniuk J., Murray J.J., Nathan R.A., Berger W.E., Johnson M., Edwards L.D., et al. Fluticasone alone or in combination with salmeterol vs. triamcinolone in asthma. Chest 116 (1999) 625-632
59. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J.H., Pauwels R.A., et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 170 (2004) 836-844
60. Bateman E.D., Jacques L., Goldfrad C., Atienza T., Mihaescu T., and Duggan M. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol 117 (2006) 563-570
61. Bateman E.D., Silins V., and Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via chlroflurocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 95 (2001) 136-146
62. Bergmann K.C., Lindemann L., Braun R., and Steinkamp G. Salmeterol/fluticasone propionate (50/250 μg) combination is superior to double dose fluticasone (500 μg) for the treatment of symptomatic moderate asthma. Swiss Med Wkly 134 (2004) 50-58
63. Boonsawat W., Goryachicina L., Jacques L., and Frith L. Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma. A placebo-controlled comparison. Clin Drug Invest 28 (2008) 101-111
64. Bouros D., Bachlitzanakis N., Kottakis J., Pfister P., Polychronopoulos V., Papadakis E., et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur Respir J 14 (1999) 627-632
65. Buhl R., Creemers J.P., Vondra V., Martelli N.A., Nava I.P., and Elkstrom T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med 97 (2003) 323-330
66. Condemi J.J., Golstein S., Kalberg C., Yancey S., Emmett A., and Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol study group. Ann Allergy Asthma Immunol 82 (1999) 383-389
67. ® alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia. Respiration 69 (2002) 427-433
68. GlaxoSmithKline Clinical Trial Register. SAM 40012 trial. Available from: http://ctr.gsk.co.uk/Summary/fluticasone_salmeterol/studylist.asp [accessed 2.11.07].
69. GlaxoSmithKline Clinical Trial Register. SAM 40090 trial. Available from: http://ctr.gsk.co.uk/Summary/fluticasone_salmeterol/studylist.asp [accessed 2.11.07].
70. GlaxoSmithKline Clinical Trial Register. SAS 30007 trial. Available from: http://ctr.gsk.co.uk/Summary/fluticasone_salmeterol/studylist.asp [accessed 2.11.07].
71. GlaxoSmithKline Clinical Trial Register. SAS 30024 trial. Available from: http://ctr.gsk.co.uk/Summary/fluticasone_salmeterol/studylist.asp [accessed 2.11.07].
72. GlaxoSmithKline Clinical Trial Register. SAS 40008 trial. Available from: http://ctr.gsk.co.uk/Summary/fluticasone_salmeterol/studylist.asp [accessed 2.11.07].
73. GlaxoSmithKline Clinical Trial Register. SLGA 5021 trial. Available from: http://ctr.gsk.co.uk/Summary/fluticasone_salmeterol/studylist.asp [accessed 2.11.07].
74. Greening A.P., Ind P.W., Northfield M., and Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344 (1994) 219-224
75. Ind P.W., Dal Negro R., Colman N.C., Fletcher C.P., Browning D., and James M.H. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med 97 (2003) 555-562
76. Kelsen S.G., Church N.L., Gillman S.A., Lanier B.Q., Emmett A.H., Rickard K.A., et al. Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. J Asthma 36 (1999) 703-715
77. Kips J.C., O'Connor B.J., Inman M.D., Svensson K., Pauwels R.A., and O'Byrne P.M. A long-term study of the anti-inflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 161 (2000) 996-1001
78. Kuna P., Creemers J.P., Vondra V., Black P.N., Lindqvist A., Nihlen U., et al. Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma. Respir Med 100 (2006) 2151-2159
79. Lalloo U.G., Malolepsky J., Kozma D., Krofta K., Ankerst J., Johansen B., et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 123 (2003) 1480-1487
80. Malone R., LaForce C., Nimmagadda S., Schoaf L., House K., Ellsworth A., et al. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol 95 (2005) 66-71
81. Matz J., Emmett A., Rickard K., and Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 107 (2001) 783-789
82. Meneses M.B., Teixeira A.L., Terra Filho J., and Vianna E.O. Inflammatory and functional effects of incresing Asthma treatment with formoterol or doublé dose budesonide. Respir Med (2008) [Epub ahead of print]
83. Mitchell C., Jenkins C., Scicchitano R., Rubinfeld A., and Kottakis J. Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulm Pharmacol Ther 16 (2003) 299-306
84. Murray J.J., Church N.L., Anderson W.H., Bernstein D.I., Wenzel S.E., Emmet A., et al. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc 20 (1999) 173-180
85. Murray J., Rosenthal R., Somerville L., Blake K., House K., Baitinger L., et al. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. Ann Allergy Asthma Immunol 93 (2004) 351-359
86. Nelson H.S., Wolfe J.D., Gross G., Greos L.S., Baitinger L., Scott C., et al. Efficacy and safety of fluticasone propionate 44 μg/salmeterol 21 μg administeredin a hydrofluoroalkane metered-dose inhalers an initial asthma maintenance treatment. Ann Allergy Asthma Immunol 91 (2003) 263-269
87. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., Runnerstrom E., Sandstrom T., Svensson K., et al. Low dose inhaled budesonide and formoterol in mildpersistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med 164 (2001) 1392-1397
88. O'Byrne P.M., Bisgaard H., Godard P.P., Pistolesi M., Palmqvist M., Zhu Y., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 (2005) 129-136
89. Pauwels R.A., Lodfdahl C.G., Postma D.S., and Tattersfield A.E. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337 (1997) 1406-1411
90. Peters S.P., Prenner B.M., Mezzanotte W.S., Martin P., and O'Brien C.D. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. Allergy Asthma Proc (2008) [Epub ahead of print]
91. Pohunek P., Kuna P., Jorup C., and De Boeck K. Budesonide/formoterol improves lung function compared with budesonide alone in children with Asthma. Pediatr Allergy Immunol 17 (2006) 458-465
92. Price D., Dutchman D., Mawson A., Bodalia B., Duggan S., and Todd P. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax 57 (2002) 791-798
93. Rabe K.F., Pizzichini E., Stallberg B., Romero S., Balanzat A.M., Atienza T., et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma. A randomized, double-blind trial. Chest 129 (2006) 246-256
94. Scicchitano R., Aalbers R., Ukena D., Manjra A., Fouquert L., Centanni S., et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 20 (2004) 1403-1418
95. Strand A.M., and Luckow A. Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. Respir Med 98 (2004) 1008-1015
96. Tal A., Simon G., Vermeulen J.H., Petru V., Cobos N., Everard M.L., et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 34 (2002) 342-350
97. The American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 356 (2007) 2027-2039
98. van Noord J.A., Lill H., Carrillo Diaz T., Greefhorst A.P., and Davies P. Clinical equivalence of salmeterol/fluticasone propionate combination product (50/500 μg) delivered via a chlorofluorocarbon-free metered dose inhaler with the Diskus in patients with moderate to severe asthma. Clin Drug Invest 21 (2001) 243-255
99. van Noord J.A., Schreurs A.J.M., Mol S.J.M., and Mulder P.G. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 54 (1999) 207-212
100. Verberne A.A.P.H., Frost C., Duiverman E.J., Grol M.H., and Kerrebijn K.F. Addition of salmeterol versus doubling dose of beclomethasone in children with asthma. Am J Respir Crit Care Med 158 (1998) 213-219
101. Vermetten F.A., Boermans A.J., Luiten W.D., Mulder P.G., and Vermue N.A. Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low-dose inhaled steroids. J Asthma 36 (1999) 97-106
102. Woolcock A., Lundback B., Ringdal N., and Jacques L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153 (1996) 1481-1488
103. Zetterstrom O., Buhl R., Mellem H., Perpiña M., Hedeman J., O'Neill S., et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 18 (2001) 262-268
104. Corren J., Korenblat P.E., Miller C.J., O'Brien C.D., and Mezzanotte W.S. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther 29 (2007) 823-843
105. Kavuru M., Melamed J., Gross G., Laforce C., House K., Prillaman B., et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 105 (2000) 1108-1116
106. Noonan M., Rosenwasser L.J., Martin P., O'Brien C.D., and O'Dowd L. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomized clinical trial. Drugs 66 (2006) 2235-2254
107. Pearlman D.S., Peden D., Condemi J.J., Weinstein S., White M., Baitinger L., et al. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. J Asthma 41 (2004) 797-806
108. Shapiro G., Lumry W., Wolfe J., Given J., White M.V., Woodring A., et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 161 (2000) 527-534
109. Bisgaard H., Le Roux P., Bjdmer D., Dymek A., Vermenlen J.H., and Hultquist C. Budesonide/formoterol maintenance plus reliever therapy. A new strategy in pediatric asthma. Chest 130 (2006) 1733-1743
110. Wechsler M.E., Lehman E., Lazarus S.C., Lemanske Jr. R.F., Boushey H.A., Deykin A., et al. -Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 173 (2006) 519-526
111. Nelson H.S. Long-acting beta-agonists in the adult asthma: evidence that these drugs are safe. Primary Care Respir J 15 (2006) 271-277
112. Federico M.J., Covar R.A., Brown E.E., Leung D.Y.M., and Spahn D. Racial differences in T-lymphocyte response to glucocorticoids. Chest 127 (2005) 571-578
113. Shrewsbury S., Pyke S., and Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 320 (2000) 1368-1373
114. Masoli M., Weatherall M., Holt S., and Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 60 (2005) 730-734
115. Nelson H.S., Chapman K.R., Pyke S.D., Johnson M., and Pritchard J.N. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 112 (2003) 29-36
116. Usmani O.S., Ito K., Maneechotesuwan K., Ito M., Johnson M., Barnes P.J., et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 172 (2005) 704-712
117. Stempel D.A., Stoloff S.W., Carranza Rosenzweig J.R., Stanford R.H., Ryskina K.L., and Legorreta A.P. Adherence to asthma controller medication regimens. Respir Med 99 (2005) 1263-1267